The FDA has granted 510(k) clearance to a Bay Area medical technology firm for its proprietary delirium monitoring solution, ...
(Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients ...
Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring SUNNYVALE, Calif., Dec. 09, ...
SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with ...
SUNNYVALE, Calif. - Ceribell, Inc. (NASDAQ:CBLL) has received 510(k) clearance from the U.S. Food and Drug Administration for its delirium monitoring solution, according to a company press release ...
(MENAFN- GlobeNewsWire - Nasdaq) Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium ...
Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring SUNNYVALE, Calif., Dec. 09, ...
CeriBell Inc. CBLL recently announced that the FDA has given 510(k) clearance for its latest delirium monitoring solution, making it the one and only FDA-cleared solution for continuous tracking of ...
This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of ...